ATE454455T1 - Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung - Google Patents

Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung

Info

Publication number
ATE454455T1
ATE454455T1 AT06719694T AT06719694T ATE454455T1 AT E454455 T1 ATE454455 T1 AT E454455T1 AT 06719694 T AT06719694 T AT 06719694T AT 06719694 T AT06719694 T AT 06719694T AT E454455 T1 ATE454455 T1 AT E454455T1
Authority
AT
Austria
Prior art keywords
guiding
production
heterologous
polypeptides
sequences
Prior art date
Application number
AT06719694T
Other languages
English (en)
Inventor
Robert Halenbeck
Elizabeth Bosch
Thomas Linnemann
Ernestine Lee
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Application granted granted Critical
Publication of ATE454455T1 publication Critical patent/ATE454455T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06719694T 2005-01-27 2006-01-27 Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung ATE454455T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64701305P 2005-01-27 2005-01-27
PCT/US2006/002951 WO2006081430A2 (en) 2005-01-27 2006-01-27 Leader sequences for directing secretion of polypeptides and methods for production thereof

Publications (1)

Publication Number Publication Date
ATE454455T1 true ATE454455T1 (de) 2010-01-15

Family

ID=36741080

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06719694T ATE454455T1 (de) 2005-01-27 2006-01-27 Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung

Country Status (9)

Country Link
US (1) US20080286834A1 (de)
EP (1) EP1841874B1 (de)
JP (2) JP2008528033A (de)
AT (1) ATE454455T1 (de)
AU (1) AU2006207999A1 (de)
CA (1) CA2589895A1 (de)
DE (1) DE602006011574D1 (de)
DK (1) DK1841874T3 (de)
WO (1) WO2006081430A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
WO2008073660A1 (en) * 2006-11-09 2008-06-19 University Of Washington Molecules and methods for treatment and detection of cancer
WO2009056330A1 (en) * 2007-10-31 2009-05-07 Eth Zurich Soluble truncated apom proteins and medical uses thereof
WO2009120810A2 (en) * 2008-03-25 2009-10-01 Cns Protein Therapeutics, Inc. Neurodegenerative disorders
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
US8470554B2 (en) * 2008-12-22 2013-06-25 St. Jude Children's Research Hospital Prokaryotic expression of soluble, active Dkk
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
PT2498799T (pt) 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
CA2928846A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
EP3943154A1 (de) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antikörper zur bindung von csf1r
DK2585098T3 (da) 2010-06-28 2014-11-03 Five Prime Therapeutics Inc Ekstracellulære FZD8-domæner og fusionsmolekyler fraekstracellulære FZD8-domæner til anvendelse ved behandling afobesitet og obesitet-relaterede lidelser
EP2444495A1 (de) * 2010-10-20 2012-04-25 Algenics Sekretion rekombinanter Polypeptide im extrazellularen Medium eines Diatoms
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
MX349293B (es) 2010-11-15 2017-07-21 Five Prime Therapeutics Inc * Tratamiento de cancer con dosis elevadas de proteinas de fusion del receptor del factor de crecimiento de fibroblastos 1 (fgfr1) solubles.
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
WO2012097238A2 (en) 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
WO2013074492A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. Methods of treating cancer
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
WO2014152940A1 (en) 2013-03-14 2014-09-25 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
EP3157957A1 (de) 2014-06-23 2017-04-26 Five Prime Therapeutics, Inc. Verfahren zur behandlung von erkrankungen mit antikörpern zur bindung des koloniestimulationsfaktor-1-rezeptors (csf1r)
HUE054012T2 (hu) 2014-10-29 2021-08-30 Five Prime Therapeutics Inc Kombinációs terápia rák ellen
US10040858B2 (en) 2014-12-22 2018-08-07 Five Prime Therapeutics, Inc. Anti-CSF1R antibodies for treating PVNS
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
CA2980460A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
EP3448414B1 (de) 2016-04-25 2024-04-17 Five Prime Therapeutics, Inc. Nope zur behandlung von pathologischem muskelschwund und schwäche
LT3535298T (lt) 2016-11-02 2021-12-27 Jounce Therapeutics, Inc. Antikūnai prieš pd-1 ir jų panaudojimas
CN109906030B (zh) 2016-11-04 2022-03-18 安健基因公司 用于产生仅重链抗体的经基因修饰的非人动物和方法
JP2020504756A (ja) * 2016-12-29 2020-02-13 ディベロップメント センター フォー バイオテクノロジーDevelopment Center For Biotechnology タンパク質薬物のin vivo半減期延長のためのキニノーゲン−1由来ペプチド
EP3601353A1 (de) 2017-03-31 2020-02-05 Five Prime Therapeutics, Inc. Kombinationstherapie gegen krebs mit anti-gitr-antikörpern
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
AU2018281334A1 (en) 2017-06-06 2019-12-19 Kindred Biosciences, Inc. Erythropoietin and analogs for veterinary use
EP4219559A3 (de) 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antikorper gegen lilrb2
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
WO2020146857A1 (en) * 2019-01-11 2020-07-16 Arbele Limited Multispecific prochemokine therapeutic proteins (park) and method of making and using thereof
CN113613664B (zh) 2019-03-01 2025-11-18 阿奇洛伊斯生物制药公司 在抗原特异性免疫细胞中调节cd160功能的方法及其用途
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
EP4114931A4 (de) * 2020-03-05 2024-05-01 Curie Co. Inc. Verfahren zur zellfreien proteinexpression von reifen polypeptiden aus zymogenen und proproteinen
KR20230077722A (ko) 2020-08-10 2023-06-01 지브이20 테라퓨틱스 엘엘씨 Igsf8을 표적화하여 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712114A (en) * 1995-06-06 1998-01-27 Basf Aktiengesellschaft Compositions for expression of proteins in host cells using a preprocollagen signal sequence
DE69902796T2 (de) * 1998-08-17 2003-08-07 Europaeisches Laboratorium Fuer Molekularbiologie (Embl) Verfahren zur reinigung von biomolekül- oder proteinkomplexen
WO2005082934A2 (en) * 2004-02-20 2005-09-09 Five Prime Therapeutics, Inc. Novel apo2l and il-24 polypeptides, polynucleotides, and methods of their use
EP1778842B8 (de) * 2004-07-22 2012-03-21 Five Prime Therapeutics, Inc. Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung

Also Published As

Publication number Publication date
AU2006207999A1 (en) 2006-08-03
WO2006081430A3 (en) 2007-04-05
WO2006081430A9 (en) 2006-11-30
US20080286834A1 (en) 2008-11-20
DE602006011574D1 (de) 2010-02-25
EP1841874B1 (de) 2010-01-06
JP2008528033A (ja) 2008-07-31
DK1841874T3 (da) 2010-05-17
CA2589895A1 (en) 2006-08-03
WO2006081430A2 (en) 2006-08-03
JP2009131268A (ja) 2009-06-18
EP1841874A2 (de) 2007-10-10

Similar Documents

Publication Publication Date Title
DE602006011574D1 (de) Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung
ATE521701T1 (de) Verbesserte konstrukte zur expression lysosomaler polypeptide
ATE478145T1 (de) Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
ATE448246T1 (de) Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
DE60137847D1 (de) Eg-vegf nukleinsäuren und polypeptide und verfahren zur deren verwendung
CY1112334T1 (el) Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων
WO2001068848A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008288A3 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
KR100468977B1 (ko) 분비 및 막횡단 폴리펩티드, 및 이를 코딩하는 핵산
DK1169442T3 (da) Secernerede polypeptider og transmembran-polypeptider og nukleinsyrer, der koder for disse
ATE448312T1 (de) Leitsequenzen zur verwendung bei der produktion von proteinen
MX345294B (es) Polipéptidos de unión quimérica de plantas para reconocimiento molecular universal.
ATE408016T1 (de) Verfahren zur herstellung und sekretion modifizierter peptide
EP4302824A3 (de) Zusammensetzungen und verfahren zur nukleinsäureexpression und proteinsekretion bei bakteroiden
WO2007124186A3 (en) Expression control elements from the lemnaceae family
PT1366161E (pt) Anticorpo anatagonista anti-pro842
ATE319858T1 (de) Modulierte sekretierte alkalische phosphatase (seap) reporter gene und polypeptide
DK1300417T3 (da) Secerneret og transmembrant polypeptid og nucleinsyre kodende derfor
DE69926415D1 (de) Sekretiertes Polypeptide und dafür kodierende Nukleinsäuren
DK1591452T3 (da) Secernerede og transmembrane polypeptider og nukleinsyrer kodende for samme
DK1621619T3 (da) Secernerede polypeptider og transmembran-polypeptider og nukleinsyrer, der koder for disse
ATE447026T1 (de) Ausgeschiedene und transmembrane polypeptide und dafür kodierende nukleinsäure
ATE489463T1 (de) Polypeptid mit einer delta-5-fettsäure- desaturierungsaktivität, für das polypeptid codierendes polynukleotid und verwendung davon.
DE69930422D1 (de) Sekretierte und transmembrane Polypeptide und dafür kodierende Nukleinsäuren
DK1241184T3 (da) Humant synaptogyrin-lignende protein og nukleinsyrer kodende for dette

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties